Consensus document on improving hypertension management in asian patients, taking into account asian characteristics

Kazuomi Kario; Chen Huan Chen; Sungha Park; Chang Gyu Park; Satoshi Hoshide; Hao Min Cheng; Qi Fang Huang; Ji Guang Wang

doi:10.1161/HYPERTENSIONAHA.117.10238

Consensus document on improving hypertension management in asian patients, taking into account asian characteristics

Kazuomi Kario, Chen Huan Chen, Sungha Park, Chang Gyu Park, Satoshi Hoshide, Hao Min Cheng, Qi Fang Huang, Ji Guang Wang

Research output: Contribution to journal › Article › peer-review

109 Citations (Scopus)

Original language	English
Pages (from-to)	375-382
Number of pages	8
Journal	Hypertension
Volume	71
Issue number	3
DOIs	https://doi.org/10.1161/HYPERTENSIONAHA.117.10238
Publication status	Published - 2018

Bibliographical note

Funding Information:
J.-G. Wang received lecture and consulting fees from Bayer, Daiichi Sankyo, MSD, Pfizer, Sanofi, Servier, and Takeda. K. Kario received research funding from Teijin Pharma Limited, Omron Healthcare Co., Ltd., Fukuda Denshi, Bayer Yakuhin Ltd., A &D Co., Ltd., Daiichi Sankyo Company, Limited, Mochida Pharmaceutical Co., Ltd, EA Pharma, Boehringer Ingelheim Japan Inc, Tanabe Mitsubishi Pharma Corporation, Shionogi & Co., Ltd., MSD K.K., Sanwa Kagaku Kenkyusho Co., Ltd., Bristol-Myers Squibb K.K., and honoraria from Takeda Pharmaceutical Company Limited and Omron Healthcare Co., Ltd. The other authors report no conflicts.

Funding Information:
The meetings held between the authors to discuss and prepare this manuscript were funded by an unrestricted educational grant from Daiichi Sankyo Co. Ltd.

Funding Information:
We acknowledge Dr Cathy Chow (Calico Communications) for editorial support, which was funded by Daiichi Sankyo Co. Ltd, and Haruo Anzai (Daiichi Sankyo Co. Ltd.) and Mitsunori Sugiyama (Daiichi Sankyo Co. Ltd.) for their logistical support.

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.1161/HYPERTENSIONAHA.117.10238

Cite this

@article{a2868aba9110420b890bcab89031aa4e,

title = "Consensus document on improving hypertension management in asian patients, taking into account asian characteristics",

author = "Kazuomi Kario and Chen, {Chen Huan} and Sungha Park and Park, {Chang Gyu} and Satoshi Hoshide and Cheng, {Hao Min} and Huang, {Qi Fang} and Wang, {Ji Guang}",

note = "Funding Information: J.-G. Wang received lecture and consulting fees from Bayer, Daiichi Sankyo, MSD, Pfizer, Sanofi, Servier, and Takeda. K. Kario received research funding from Teijin Pharma Limited, Omron Healthcare Co., Ltd., Fukuda Denshi, Bayer Yakuhin Ltd., A &D Co., Ltd., Daiichi Sankyo Company, Limited, Mochida Pharmaceutical Co., Ltd, EA Pharma, Boehringer Ingelheim Japan Inc, Tanabe Mitsubishi Pharma Corporation, Shionogi & Co., Ltd., MSD K.K., Sanwa Kagaku Kenkyusho Co., Ltd., Bristol-Myers Squibb K.K., and honoraria from Takeda Pharmaceutical Company Limited and Omron Healthcare Co., Ltd. The other authors report no conflicts. Funding Information: The meetings held between the authors to discuss and prepare this manuscript were funded by an unrestricted educational grant from Daiichi Sankyo Co. Ltd. Funding Information: We acknowledge Dr Cathy Chow (Calico Communications) for editorial support, which was funded by Daiichi Sankyo Co. Ltd, and Haruo Anzai (Daiichi Sankyo Co. Ltd.) and Mitsunori Sugiyama (Daiichi Sankyo Co. Ltd.) for their logistical support.",

year = "2018",

doi = "10.1161/HYPERTENSIONAHA.117.10238",

language = "English",

volume = "71",

pages = "375--382",

journal = "Hypertension",

issn = "0194-911X",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Consensus document on improving hypertension management in asian patients, taking into account asian characteristics

AU - Kario, Kazuomi

AU - Chen, Chen Huan

AU - Park, Sungha

AU - Park, Chang Gyu

AU - Hoshide, Satoshi

AU - Cheng, Hao Min

AU - Huang, Qi Fang

AU - Wang, Ji Guang

N1 - Funding Information: J.-G. Wang received lecture and consulting fees from Bayer, Daiichi Sankyo, MSD, Pfizer, Sanofi, Servier, and Takeda. K. Kario received research funding from Teijin Pharma Limited, Omron Healthcare Co., Ltd., Fukuda Denshi, Bayer Yakuhin Ltd., A &D Co., Ltd., Daiichi Sankyo Company, Limited, Mochida Pharmaceutical Co., Ltd, EA Pharma, Boehringer Ingelheim Japan Inc, Tanabe Mitsubishi Pharma Corporation, Shionogi & Co., Ltd., MSD K.K., Sanwa Kagaku Kenkyusho Co., Ltd., Bristol-Myers Squibb K.K., and honoraria from Takeda Pharmaceutical Company Limited and Omron Healthcare Co., Ltd. The other authors report no conflicts. Funding Information: The meetings held between the authors to discuss and prepare this manuscript were funded by an unrestricted educational grant from Daiichi Sankyo Co. Ltd. Funding Information: We acknowledge Dr Cathy Chow (Calico Communications) for editorial support, which was funded by Daiichi Sankyo Co. Ltd, and Haruo Anzai (Daiichi Sankyo Co. Ltd.) and Mitsunori Sugiyama (Daiichi Sankyo Co. Ltd.) for their logistical support.

PY - 2018

Y1 - 2018

UR - http://www.scopus.com/inward/record.url?scp=85047941806&partnerID=8YFLogxK

U2 - 10.1161/HYPERTENSIONAHA.117.10238

DO - 10.1161/HYPERTENSIONAHA.117.10238

M3 - Article

C2 - 29311253

AN - SCOPUS:85047941806

SN - 0194-911X

VL - 71

SP - 375

EP - 382

JO - Hypertension

JF - Hypertension

IS - 3

ER -

Consensus document on improving hypertension management in asian patients, taking into account asian characteristics

Bibliographical note

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this